Interestingly, though, more than 20% of patients in the iPDT series survived more than two years after malignant glioma recurrence irrespective of time to PDT and later salvage treatments and even with MGMT-unmethylated primary glioblastomas. The gene discussed is MGMT; the disease is malignant glioma.